Critères d'inclusion : - Male or female, age superior to 18 years.
- Histologically confirmed metastatic colorectal adenocarcinoma.
- Measurable disease according to the RECIST 1.1 guideline
- ECOG performance status <3.
- Disease requiring IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab) every 14 days
- No prior chemotherapy for this adenocarcinoma with the exception of adjuvant chemotherapy
- Signed and dated informed consent document.
Critères de non-inclusion :
- Medical history of cancer within 5 years
- Medical contraindication for a treatment consisted of IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab)
- Patient with known psychiatric or substance abuse disorders that could interfere with cooperation with the requirements of the study